Royce & Associates LP Purchases Shares of 420,569 ADMA Biologics, Inc. (NASDAQ:ADMA)

Royce & Associates LP purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 420,569 shares of the biotechnology company’s stock, valued at approximately $7,213,000. Royce & Associates LP owned about 0.18% of ADMA Biologics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund lifted its position in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth $61,858,000. EWG Elevate Inc. purchased a new position in ADMA Biologics in the fourth quarter worth $480,000. Raymond James Financial Inc. bought a new position in ADMA Biologics in the fourth quarter valued at $19,076,000. Finally, Citigroup Inc. raised its position in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after purchasing an additional 277,138 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

ADMA stock opened at $18.71 on Wednesday. The firm has a market cap of $4.42 billion, a P/E ratio of 66.82 and a beta of 0.60. The firm’s fifty day moving average is $16.67 and its 200 day moving average is $17.98. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.